Homocystinuria (HCU) is a rare autosomal recessive inherited metabolic disorder most commonly caused by cystathionine β-synthase (CBS) deficiency, leading to markedly elevated plasma homocysteine (often >100 µmol/L) and methionine, with multi-organ complications affecting the eyes, skeleton, vasculature, and CNS. [1-2] Global prevalence is estimated at ~1 in 200,000–300,000, with higher rates in populations with consanguinity and those of Irish descent. [2-3]
The following figure illustrates the key metabolic pathways involved in homocysteine metabolism and the enzymatic defects underlying homocystinuria:
1. History
- Key HPI questions: Age of onset of visual changes (myopia, lens subluxation), developmental milestones, history of thromboembolic events (DVT, PE, stroke), skeletal complaints (scoliosis, fractures), psychiatric symptoms [1]
- Symptom characterization: Progressive myopia, sudden vision changes (lens dislocation), bone pain/fractures, limb pain/swelling (thrombosis), cognitive decline, behavioral changes [1]
- Timing/triggers: Thromboembolism may be triggered by dehydration, immobilization, surgery, oral contraceptive use, or pregnancy/postpartum period [1]
- Associated symptoms: Seizures, dystonia, psychiatric manifestations (hallucinations, delusions, anxiety), malar flush, livedo reticularis [1][5]
- Important negatives: Absence of joint hypermobility (distinguishes from Marfan syndrome); absence of megaloblastic anemia (distinguishes CBS deficiency from remethylation defects) [1][6]
2. Alarm Features
- Acute stroke (ischemic or hemorrhagic) — ~50% of untreated patients have a thromboembolic event by age 30; one-third are cerebrovascular [7]
- Cerebral venous sinus thrombosis — can be a presenting sign even in childhood [1]
- Acute lens dislocation with sudden vision loss — requires urgent ophthalmology referral [1]
- Altered mental status — may indicate stroke or cerebral edema (especially if on betaine with methionine >1,000 µmol/L) [1]
- Acute psychiatric event (psychosis, hallucinations) [1][5]
- Neonatal apnea/respiratory failure — risk with pyridoxine doses near or >200 mg/day in newborns [1]
3. Medications
- Pyridoxine (vitamin B6): First-line for B6-responsive patients (~40%); target dose ~200 mg/day or lowest dose achieving tHcy <50 µmol/L; typical adult dose 2–5 mg/kg/day; avoid doses >500 mg/day (peripheral neuropathy risk above 900 mg/day) [1][8]
- Betaine (Cystadane): Alternative remethylation pathway; adults: 3 g BID initial; children: 50 mg/kg BID, titrated weekly; risk of cerebral edema if methionine exceeds ~1,000 µmol/L [1]
- Folic acid: 5 mg/day if RBC folate is low [1]
- Hydroxocobalamin (B12): 1 mg IM monthly if serum B12 is low [1]
- Methionine-free amino acid formula: Essential supplement with methionine-restricted diet to prevent protein malnutrition [1]
Contraindicated/Avoid
- Oral contraceptives in affected females (thrombotic risk) [1]
- Nitrous oxide (inactivates methionine synthase, worsens homocysteine metabolism) [1]
- Dehydration and immobilization (thrombotic risk) [1]
4. Diet
- Methionine-restricted diet: Primary therapy for B6-nonresponsive patients; restricts natural protein intake and supplements with methionine-free amino acid mixture providing cysteine and other essential amino acids [1][8]
- Cysteine supplementation: May be an essential amino acid in CBS deficiency since the transsulfuration pathway is blocked [1]
- Adequate hydration: Critical to reduce thrombotic risk, especially during illness [1]
- Long-term: Diet is continued lifelong unless tHcy targets are achieved entirely by pyridoxine; dietary adherence is less well tolerated if begun in mid-childhood or later [1]
- Breastfeeding: May be continued in combination with methionine-free amino acid infant formula [1]
5. Review of Systems
- Eyes: Myopia, blurred vision, photophobia, lens subluxation symptoms [1]
- Musculoskeletal: Tall stature, long limbs, scoliosis, pectus deformity, fractures, bone pain [1]
- Vascular: Limb swelling/pain (DVT), chest pain/dyspnea (PE), focal neurologic deficits (stroke) [1]
- Neurologic: Developmental delay, seizures, movement disorders, dystonia [1]
- Psychiatric: Anxiety, ADHD, psychosis, behavioral changes, sleep disturbances [5]
- Dermatologic: Hypopigmentation of skin/hair, malar flush, livedo reticularis [1]
- GI: Pancreatitis (uncommon but reported) [1]
6. Collateral History and Family History
- Autosomal recessive inheritance — inquire about consanguinity, affected siblings [1]
- Newborn screening results — NBS detects elevated methionine (not homocysteine); B6-responsive forms may be missed on NBS [1][9]
- Family history of early thromboembolism, stroke, or lens dislocation in young relatives [1]
- Ethnic background: Higher prevalence in Irish descent and populations with high consanguinity [3]
- Concurrent Factor V Leiden significantly increases thrombotic risk [7][10]
7. Risk Factors
- Genetic: Autosomal recessive; CBS gene on chromosome 21q22.3; >150 mutations described; G307S (B6-nonresponsive) and I278T (typically B6-responsive) are most common [3][11]
- Consanguinity and Irish descent [3]
- Thrombotic risk amplifiers: Surgery, immobilization, dehydration, pregnancy/postpartum, oral contraceptives, concurrent Factor V Leiden [1][10]
- Poor dietary/medication compliance — major contributor to elevated tHcy and complications [8]
8. Differential Diagnosis
- Marfan syndrome: Shares marfanoid habitus, ectopia lentis, arachnodactyly; distinguished by joint hypermobility (present in Marfan, absent in HCU), upward lens dislocation (Marfan) vs. downward (HCU), and normal homocysteine/methionine in Marfan [1][7]
- MTHFR deficiency: Elevated homocysteine but low methionine; may have megaloblastic anemia, seizures, cognitive decline [5-6]
- Cobalamin metabolism defects (CblC/D): Elevated homocysteine + methylmalonic acidemia + macrocytic anemia; low methionine [5-6]
- Sulfite oxidase deficiency: Ectopia lentis but normal homocysteine [1]
- Methionine adenosyltransferase (MAT) I/III deficiency: Elevated methionine but normal/mildly elevated homocysteine [1]
- Acquired hyperhomocysteinemia: B6/B12/folate deficiency; typically milder (15–100 µmol/L); must be excluded first [6-7]
9. Past Medical History
- Prior thromboembolic events (DVT, PE, stroke, cerebral venous sinus thrombosis) [1]
- Ectopia lentis or eye surgeries [1]
- Skeletal surgeries (scoliosis correction, pectus repair) [1]
- Developmental delay, intellectual disability, seizure history [1]
- Psychiatric diagnoses [5]
- Osteoporotic fractures [1]
- Newborn screening results and pyridoxine responsiveness status [1]
10. Physical Exam
- General: Tall, thin, marfanoid habitus; dolichostenomelia (disproportionately long limbs); arachnodactyly [1]
- Eyes: Iridodonesis (trembling iris — sign of lens subluxation); ectopia lentis (typically inferonasal displacement); high myopia [1]
- Skin: Fair complexion, hypopigmentation of hair/skin, malar flush, livedo reticularis [1]
- Skeletal: Pectus excavatum/carinatum, scoliosis/kyphosis, genu valgum, pes cavus, high-arched palate; no joint hypermobility (unlike Marfan) [1]
- Neurologic: Assess for focal deficits (stroke), dystonia, seizures, cognitive function [1]
- Vascular: Limb swelling/tenderness (DVT), signs of PE [1]
11. Lab Studies
- Plasma total homocysteine (tHcy): Markedly elevated, often >100 µmol/L (normal <15 µmol/L); must be measured off B6 supplementation for 2 weeks for diagnostic accuracy [1]
- Plasma amino acids: Elevated methionine (high/normal in CBS deficiency; low in remethylation defects); low cystathionine; elevated methionine-to-cystathionine ratio [1][6]
- CBC: To evaluate for macrocytic anemia (suggests remethylation defect rather than CBS deficiency) [6]
- Urine methylmalonic acid: Elevated in cobalamin defects; normal in CBS deficiency and MTHFR deficiency [6]
- Serum B12, folate, RBC folate: To exclude acquired causes [1][6]
- Monitoring on treatment: Plasma tHcy (target <100 µmol/L for nonresponders, <50 µmol/L for B6-responsive), methionine, CBC, iron studies, prealbumin, 25-OH vitamin D, zinc, lipid profile [1]
- Sarcosine: Elevated >5 µmol/L is 97% sensitive and 95% specific for betaine compliance [12]
12. Imaging
- DXA scan: Assess bone mineral density; reduced density common in lumbar spine and hip; recommended every 3–5 years from adolescence [1]
- Lateral lumbar spine radiographs: May detect osteoporosis [1]
- Scoliosis radiographs: As clinically indicated [1]
- Brain MRI/CT: If stroke or cerebral edema suspected [1]
- CT angiography/MR venography: If cerebral venous sinus thrombosis suspected [1]
- Doppler ultrasound: For suspected DVT [1]
13. Special Tests
- Pyridoxine challenge test: Determines B6 responsiveness; administer pyridoxine and measure tHcy response; critical for guiding treatment strategy [1]
- CBS enzyme activity assay: Performed on cultured fibroblasts (skin biopsy) for definitive biochemical confirmation [10]
- Molecular genetic testing: CBS gene sequencing; identifies specific mutations (I278T = typically B6-responsive; G307S = B6-nonresponsive) [3]
- Newborn screening (NBS): Detects elevated methionine via tandem mass spectrometry on dried blood spots; some programs perform second-tier homocysteine testing [1]
- Prenatal diagnosis: Available via enzyme assay on amniocytes or molecular testing if familial mutations are known [10]
14. ECG
- No specific ECG findings characteristic of homocystinuria
- ECG indicated if presenting with chest pain, dyspnea, or suspected PE/cardiac event
- Consider ECG in the setting of acute thromboembolic events to evaluate for right heart strain (PE) or ischemia
15. Assessment
Classical HCU (CBS deficiency) is a multi-system disorder with variable expressivity. Severity stratification depends primarily on pyridoxine responsiveness: [13]
- B6-responsive (~40%): Milder phenotype; later onset (often adulthood); may present solely with thromboembolism; generally achieves tHcy <50 µmol/L on treatment [7-8]
- B6-nonresponsive/partial responders: More severe; childhood onset with developmental delay, ectopia lentis (by age 8 in most untreated), skeletal abnormalities, and early thromboembolism [1][8]
Key complications: Thromboembolism is the major cause of early death — ~50% of untreated patients have an event by age 30. [7][14] Early treatment detected by NBS dramatically reduces risk: thromboembolism risk ratio 0.073 and lens dislocation risk ratio 0.069 in treated vs. untreated patients. [8]
16. Treatment Plan
Initial stabilization (ED/acute setting)
- If presenting with stroke: Standard acute stroke management; avoid dehydration and immobilization; immediately inform metabolic specialist [1]
- If presenting with acute lens dislocation: Urgent ophthalmology referral [1]
- Fever/illness: Continue regular metabolic treatment; antipyretics; treat underlying infection; avoid dehydration (thrombotic risk) [1]
Chronic management
- B6-responsive: Pyridoxine ~200 mg/day (2–5 mg/kg/day adult dose); target tHcy <50 µmol/L [1]
- B6-nonresponsive: Methionine-restricted diet + methionine-free amino acid formula + betaine (adults: 3 g BID; children: 50 mg/kg BID, titrated) [1][8]
- Adjunctive: Folic acid 5 mg/day (if low RBC folate); hydroxocobalamin 1 mg IM monthly (if low B12) [1]
- Thromboprophylaxis: Aggressive hydration; early mobilization; consider anticoagulation perioperatively per metabolic/hematology guidance [1]
- Emerging therapies: Enzyme replacement (pegtibatinase, SYNT-202), gene therapy, and pharmacological chaperones are in development; liver transplantation remains the only definitive treatment for severe B6-nonresponsive cases [2]
17. Disposition
- Admit if: Acute thromboembolic event (stroke, DVT, PE), acute lens dislocation requiring surgery, altered mental status, suspected cerebral edema (betaine-related hypermethioninemia), metabolic decompensation during illness [1]
- Observation: Febrile illness with risk of dehydration in known HCU patient; ensure adequate hydration and continuation of metabolic treatment [1]
- Discharge criteria: Hemodynamically stable, able to tolerate oral medications and diet, no acute thromboembolic or neurologic concerns, metabolic specialist informed [1]
- Specialist consultation triggers: Metabolic genetics (always), ophthalmology (lens/vision changes), hematology (thromboembolism), orthopedics (scoliosis/skeletal deformity), neurology (seizures/stroke), psychiatry (behavioral/psychiatric manifestations) [1]
18. Follow Up / Return Precautions
- Follow-up timing: Metabolic specialist and dietitian visits per severity; plasma tHcy and amino acids monitored regularly (frequency individualized); ophthalmology at least annually; DXA every 3–5 years from adolescence [1]
- Return immediately for: Sudden vision changes, limb swelling/pain, chest pain/dyspnea, focal neurologic deficits, altered mental status, severe headache, acute psychiatric symptoms [1]
- Patient counseling: Lifelong treatment adherence is critical — noncompliance leads to ectopia lentis, osteoporosis, and thromboembolism; avoid oral contraceptives, nitrous oxide, dehydration, and prolonged immobilization [1][8-9]
- Expected course: With early diagnosis and compliant treatment, most complications are preventable; B6-responsive patients have the best prognosis; noncompliance is the primary driver of poor outcomes [8-9][11]
References
1. Homocystinuria due to Cystathionine Beta-Synthase Deficiency. — Sacharow SJ, Levy HL GeneReviews® [Internet]. 2025.
2. Homocystinuria: Advances in Metabolic and Molecular Therapies Targeting Homocysteine Pathways (Review). — Althubity AA. Molecular Medicine Reports. 2026.
3. Newborn Screening for Homocystinuria. — Walter JH, Jahnke N, Remmington T. The Cochrane Database of Systematic Reviews. 2015.
4. Inherited Metabolic Disorders and Stroke Part 2: Homocystinuria, Organic Acidurias, and Urea Cycle Disorders. — Testai FD, Gorelick PB. Archives of Neurology. 2010.
5. Homocystinuria due to Deficiency of N(5,10)-Methylenetetrahydrofolate Reductase Activity. — Umair M, Alfadhel M GeneReviews® [Internet]. 2025.
6. Homocystinuria Diagnosis and Management: It Is Not All Classical. — Gerrard A, Dawson C. Journal of Clinical Pathology. 2022.
7. Genetics of Ischaemic Stroke. — Dichgans M. The Lancet. Neurology. 2007.
8. Cystathionine Β-Synthase Deficiency in the E-Hod Registry-Part II: Dietary and Pharmacological Treatment. — Morris AAM, Sokolová J, Pavlíková M, et al. Journal of Inherited Metabolic Disease. 2025.
9. Reduction of False Negative Results in Screening of Newborns for Homocystinuria. — Peterschmitt MJ, Simmons JR, Levy HL. The New England Journal of Medicine. 1999.
10. Coexistence of Hereditary Homocystinuria and Factor V Leiden — Effect on Thrombosis. — Mandel H, Brenner B, Berant M, et al. The New England Journal of Medicine. 1996.
11. The Molecular Basis of Cystathionine Beta-Synthase Deficiency in Dutch Patients With Homocystinuria: Effect of CBS Genotype on Biochemical and Clinical Phenotype and on Response to Treatment. — Kluijtmans LA, Boers GH, Kraus JP, et al. American Journal of Human Genetics. 1999.
12. Laboratory Evaluation of Homocysteine Remethylation Disorders and Classic Homocystinuria: Long-Term Follow-Up Using a Cohort of 123 Patients. — De Biase I, Gherasim C, La'ulu SL, et al. Clinica Chimica Acta; International Journal of Clinical Chemistry. 2020.
13. Komrower Memorial Lecture 2023. Molecular Basis of Phenotype Expression in Homocystinuria: Where Are We 30 years Later?. — Kožich V, Majtan T. Journal of Inherited Metabolic Disease. 2024.
14. Homocysteine and Atherothrombosis. — Welch GN, Loscalzo J. The New England Journal of Medicine. 1998.